RXi Acquires Ownership of Previously Licensed RNAi Delivery Technology

In July, RXi announced that it had acquired an exclusive licensed to the technology, which was developed by a Boulder, Colo.-based biotech firm co-founded by the company's CSO.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories